I could be wrong in my thinking, but from memory ARDS trial (past and future) was interlinked with GVHD. The design of the ARDS trial was purposely done so that they could use that data for GVHD.
SI has already mentioned that the Covid-19 ARDS will undergo an expanded trial, perhaps they may get accelerated approval for GVHD, in conjunction with the Covid-19 ARDS trial, data from this trial, will be used for the final BLA / Approval submission.
Ann: Update on FDA Meeting for Remestemcel-L in Paediatric GvHD, page-102
-
- There are more pages in this discussion • 110 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |